Sanofi's Dengvaxia: ACIP Decision On Use Will Hinge On Screening Test

Whether the US Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) eventually recommends use of Sanofi's dengue vaccine Dengvaxia will depend on several factors, including the number of hospitalizations that might occur in children not previously infected with dengue who receive the vaccine. But there must first be a screening test to confirm prior infection.

ACIP discussed its ongoing consideration of Dengvaxia at its 24 October meeting